But monoclonal antibody (mAb) therapy has immense promise and are quietly being developed
New pre-print by @bart_haagmans et al. Note low inflammation in MAb treated group (hampsters)
biorxiv.org/content/10.110…

Any thoughts on transmission?
Interesting the differential between benefits seen in lung inflammation vs. little difference in RNA in nasal tissue.